Eli Lilly And Stock Buy Hold or Sell Recommendation
| LLY Stock | USD 745.95 4.82 0.64% |
Considering the 90-day investment horizon and complete risk avoidance on your part, our recommendation regarding Eli Lilly and is 'Strong Sell'. Macroaxis provides Eli Lilly buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LLY positions. The advice algorithm takes into account all of Eli Lilly's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eli Lilly's buy or sell advice are summarized below:
Real Value 732.73 | Target Price 603.57 | Hype Value 753.04 | Market Value 745.95 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eli Lilly and given historical horizon and risk tolerance towards Eli Lilly. When Macroaxis issues a 'buy' or 'sell' recommendation for Eli Lilly and, the advice is generated through an automated system that utilizes algorithms and statistical models.
Eli |
Execute Eli Lilly Buy or Sell Advice
The Eli recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eli Lilly and. Macroaxis does not own or have any residual interests in Eli Lilly and or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eli Lilly's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Eli Lilly Trading Alerts and Improvement Suggestions
| Over 84.0% of the company shares are owned by institutional investors | |
| On 8th of March 2024 Eli Lilly paid $ 1.3 per share dividend to its current shareholders | |
| Latest headline from zacks.com: Eli Lilly Stock Dips While Market Gains Key Facts |
Eli Lilly Returns Distribution Density
The distribution of Eli Lilly's historical returns is an attempt to chart the uncertainty of Eli Lilly's future price movements. The chart of the probability distribution of Eli Lilly daily returns describes the distribution of returns around its average expected value. We use Eli Lilly and price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eli Lilly returns is essential to provide solid investment advice for Eli Lilly.
| Mean Return | 0.25 | Value At Risk | -2.31 | Potential Upside | 3.18 | Standard Deviation | 1.62 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eli Lilly historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eli Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eli Lilly is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eli Lilly and backward and forwards among themselves. Eli Lilly's institutional investor refers to the entity that pools money to purchase Eli Lilly's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2023-12-31 | 16 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 12.7 M | Wellington Management Company Llp | 2023-12-31 | 11.8 M | Norges Bank | 2023-12-31 | 10.3 M | Bank Of America Corp | 2023-12-31 | 9.9 M | Goldman Sachs Group Inc | 2023-12-31 | 9.4 M | Northern Trust Corp | 2023-12-31 | 9.1 M | Jennison Associates Llc | 2023-12-31 | 7.6 M | Capital Research Global Investors | 2023-12-31 | 7.6 M | Lilly Endowment Inc | 2023-12-31 | 99.8 M | Vanguard Group Inc | 2023-12-31 | 71.6 M |
Eli Lilly Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (258.7M) | (533.4M) | (235.9M) | (599.7M) | (1.4B) | (1.4B) | |
| Change In Cash | (5.7B) | 1.3B | 161.4M | (1.8B) | 751.6M | 789.2M | |
| Free Cash Flow | 3.5B | 4.5B | 5.4B | 4.6B | (3.2B) | (3.0B) | |
| Depreciation | 1.2B | 1.3B | 1.5B | 1.5B | 1.5B | 1.0B | |
| Other Non Cash Items | (3.4B) | (444.2M) | 1.6B | 1.1B | 2.2B | 2.4B | |
| Dividends Paid | 2.4B | 2.7B | 3.1B | 3.5B | (4.1B) | (3.9B) | |
| Capital Expenditures | 1.4B | 2.0B | 1.9B | 2.5B | 7.4B | 7.8B | |
| Net Income | 8.3B | 6.2B | 5.6B | 6.2B | 5.2B | 3.1B | |
| End Period Cash Flow | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.4B | |
| Investments | 456.2M | 516.7M | (166M) | (244M) | (7.2B) | (6.8B) | |
| Change Receivables | (357M) | (996.7M) | (127.2M) | (299.6M) | (269.6M) | (283.1M) | |
| Net Borrowings | 4.7B | 291.6M | 501.4M | (62M) | (71.3M) | (67.7M) | |
| Change To Netincome | 653.3M | (270.6M) | 1.2B | (668.4M) | (601.6M) | (571.5M) |
Eli Lilly Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eli Lilly or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eli Lilly's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eli stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.21 | |
β | Beta against NYSE Composite | 0.74 | |
σ | Overall volatility | 1.63 | |
Ir | Information ratio | 0.12 |
Eli Lilly Volatility Alert
Eli Lilly and has relatively low volatility with skewness of 0.51 and kurtosis of 1.74. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eli Lilly's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eli Lilly's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eli Lilly Implied Volatility
Eli Lilly's implied volatility exposes the market's sentiment of Eli Lilly and stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eli Lilly's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eli Lilly stock will not fluctuate a lot when Eli Lilly's options are near their expiration.
Eli Lilly Fundamentals Vs Peers
Comparing Eli Lilly's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eli Lilly's direct or indirect competition across all of the common fundamentals between Eli Lilly and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eli Lilly or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eli Lilly's fundamental indicators could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eli Lilly to competition |
| Fundamentals | Eli Lilly | Peer Average |
| Return On Equity | 0.48 | -0.31 |
| Return On Asset | 0.12 | -0.14 |
| Profit Margin | 0.15 % | (1.27) % |
| Operating Margin | 0.34 % | (5.51) % |
| Current Valuation | 699.33 B | 16.62 B |
| Shares Outstanding | 950.77 M | 571.82 M |
| Shares Owned By Insiders | 0.16 % | 10.09 % |
| Shares Owned By Institutions | 84.31 % | 39.21 % |
| Number Of Shares Shorted | 5.42 M | 4.71 M |
| Price To Earning | 54.92 X | 28.72 X |
| Price To Book | 66.34 X | 9.51 X |
| Price To Sales | 20.94 X | 11.42 X |
| Revenue | 34.12 B | 9.43 B |
| Gross Profit | 21.91 B | 27.38 B |
| EBITDA | 12.46 B | 3.9 B |
| Net Income | 5.24 B | 570.98 M |
| Cash And Equivalents | 2.07 B | 2.7 B |
| Cash Per Share | 2.97 X | 5.01 X |
| Total Debt | 25.23 B | 5.32 B |
| Debt To Equity | 1.58 % | 48.70 % |
| Current Ratio | 1.13 X | 2.16 X |
| Book Value Per Share | 11.98 X | 1.93 K |
| Cash Flow From Operations | 4.24 B | 971.22 M |
| Short Ratio | 1.82 X | 4.00 X |
| Earnings Per Share | 5.82 X | 3.12 X |
| Price To Earnings To Growth | 1.43 X | 4.89 X |
| Target Price | 826.53 | |
| Number Of Employees | 43 K | 18.84 K |
| Beta | 0.37 | -0.15 |
| Market Capitalization | 713.81 B | 19.03 B |
| Total Asset | 64.01 B | 29.47 B |
| Retained Earnings | 10.31 B | 9.33 B |
| Working Capital | (1.57 B) | 1.48 B |
Note: Payment of 2142 shares by Donald Zakrowski of Eli Lilly subject to Rule 16b-3 [view details]
Eli Lilly Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eli . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 19240.25 | |||
| Daily Balance Of Power | (0.57) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 747.99 | |||
| Day Typical Price | 747.31 | |||
| Price Action Indicator | (4.44) | |||
| Period Momentum Indicator | (4.82) | |||
| Relative Strength Index | 75.13 |
About Eli Lilly Buy or Sell Advice
When is the right time to buy or sell Eli Lilly and? Buying financial instruments such as Eli Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 16.9B | 16.2B | 25.2B | 26.5B | Total Assets | 48.8B | 49.5B | 64.0B | 67.2B |
Use Investing Ideas to Build Portfolios
In addition to having Eli Lilly in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eli Lilly Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.82 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.